Skip to content
FrontierPicks

Watching

MYGN · Myriad Genetics, Inc.

Conviction · Low Business pivot Catalyst · Medtech & diagnostics

Updated ·

Against its published line

Above its line on the last close.

How to read this

The red mark is the published kill line — the price that would prove the thesis wrong. The dot is where the name closed on 30 October 2026; a dot left of the mark has closed through its line.

Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row reads well clear, with a hollow dot to show the figure is off the drawn scale. Rows run tightest first.

How a pick is graded

MYGNMyriad Genetics, Inc.
$4.21
$6.35
+50.8%well clear

Kill line

A daily close below $4.21, the 19 October 2026 close before the Labcorp deal, which would erase the entire deal gain; a year-over-year fall in revenue per test, a guidance cut beyond the prenatal carve-out, or termination of the sale would confirm it.

Not a pickResearch coverage at low conviction. A medium-or-higher call would open a pick on the scoreboard.

Catalyst (3 days ago)

How picks are graded →

The thesis

Myriad Genetics shares look more likely to lag the S&P 500 than lead it over the next three months. They closed at $6.35 on 30 October 2026, after doubling in three months, and sit above every published analyst target except Craig-Hallum's $8.00. The third-quarter report on 4 November 2026 settles it by showing whether revenue per test has stopped falling in the business Myriad is keeping.

The $210 million sale of the prenatal business to Labcorp, announced 20 October 2026, removed the funding worry. Myriad held $115.2 million of cash at the end of the second quarter, when adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) was -$16.9 million (30 July 2026 release). The sale closes in early 2027, subject to regulatory clearance (company 8-K, 20 October 2026). The cash comes in only at closing.

No company news, filing or analyst action has appeared since 22 October 2026, when Myriad published MONSTAR-SCREEN-3 data. The shares moved from $6.29 on 27 October 2026 to $6.35 on 30 October 2026. That small move leaves the case where the previous note put it: the deal is priced in, and the operating numbers are not yet known.

Bullish and bearish views on Myriad Genetics, Inc.

The bull case on Myriad Genetics, Inc. (MYGN), in brief: Prenatal sale brings in $210 million. The bear case: The price is ahead of the analysts.

Bull case

  • Prenatal sale brings in $210 million. Labcorp agreed on 20 October 2026 to buy the Prequel, Foresight, SneakPeek and FirstGene tests for $210 million in cash plus inventory value. Chief executive Sam Raha said the deal should add to Myriad's revenue growth and profitability.
  • The loudest bear has stepped back. Piper Sandler upgraded the shares from Underweight to Neutral on 20 October 2026 with a $5.00 target, per a MarketBeat report of 22 October 2026. On 1 September 2026 it had cut its target to $2.00 and questioned whether Myriad could reach profitability without selling assets.
  • The remaining lines grew in volume. Hereditary-cancer volume rose 8% and Cancer Care Continuum volume 6% year over year in the second quarter (30 July 2026 release). Prenatal Health, the unit being sold, was the declining line, with volume down 9% to 144,000 tests.
  • Minimal residual disease (MRD) data keeps coming. On 22 October 2026 Myriad released MONSTAR-SCREEN-3 data showing its Precise MRD test detecting residual disease in colorectal and pancreatic cancers. On 8 October 2026 it announced a prostate-cancer genomic-instability collaboration with SOPHiA GENETICS.
  • Craig-Hallum still sees $8. Craig-Hallum's John Wilkin raised his target from $4.00 to $8.00 on 2 October 2026 with a Buy rating (Benzinga). His case included a prenatal divestiture, which has now been agreed.

Bear case

  • The price is ahead of the analysts. MarketBeat's consensus target was $4.77 on 22 October 2026, from one Buy, six Holds and one Sell. Piper Sandler's $5.00 and TD Cowen's $4.50 (raised 13 October 2026) both sit below the $6.35 close of 30 October 2026.
  • Revenue per test was still falling. Second-quarter revenue was $190.7 million, down 11% year over year, and average revenue per test fell 9% (30 July 2026 release). The company cited higher denial rates and prior-authorization demands, which the prenatal sale does not fix.
  • The cash arrives in 2027. The 8-K of 20 October 2026 puts closing in early 2027, after regulatory clearance. Until then the company runs with negative adjusted EBITDA and no profitability guidance, which has been suspended since 30 July 2026.
  • The sale shrinks the revenue line. Labcorp expects the prenatal business to contribute about $160 million of revenue in its first year (joint release, 20 October 2026). Myriad's FY2026 revenue guide of $770–790 million includes that business until closing, so the guide has to be restated.
  • The run has been steep. The shares rose 100.3% over three months to 30 October 2026, and the 14-day relative strength index (RSI) stood at 78.5, a reading usually described as overbought.

Price setup

The shares closed at $6.35 on 30 October 2026 in split- and dividend-adjusted daily closes. That is 22.4% below the 52-week high of $8.18. The close of $4.21 on 19 October 2026, the session before the Labcorp announcement, marks the level that would erase the whole deal gain.

On 20 October 2026 the shares rose as much as 36.85% intraday to $5.76 (Benzinga). They have since held above that level. The narrative is maturing: the deal is well known, no fresh company news has appeared since 22 October 2026, and the price has moved sideways for a week.

Crowding signs are visible. The RSI of 78.5, the 100.3% three-month gain and an earnings report two sessions away all point to a crowded stock heading into the print. At a single-digit share price, single analyst notes and company announcements have moved the shares sharply, as on 1 September 2026 and 20 October 2026.

The medtech and diagnostics group, including Glaukos, Quidel and DexCom, has cooled from heating to maturing in weekly readings since 18 October 2026. A cooling group gives no tailwind, so the 4 November 2026 numbers have to carry the case on their own.

Catalysts, next 30 days

  • ~31 January 2027, est. Labcorp sale closing. The company guides to early 2027. Any antitrust second request or a later closing date would push back the $210 million cash payment.
  • Undated — Medicare MolDX coverage decision for Precise MRD in breast cancer. Coverage would turn MRD into billable revenue. Without it, MRD remains a cost line.

Elapsed catalysts

  • 4 November 2026, after the close — Q3 2026 results and 4:30 p.m. ET call. This is the first read on revenue per test since July, the first restatement of the $770–790 million FY2026 revenue guide for the prenatal sale, and the earliest point to reinstate adjusted EBITDA guidance. (passed 3d ago)

What would change the view

The case for lagging the index breaks if the 4 November 2026 report shows average revenue per test flat or rising year over year in the businesses Myriad is keeping. A reinstated adjusted EBITDA outlook, or analyst targets raised above the $6.35 close of 30 October 2026, would also show the deal gain has operating support. A positive MolDX decision for Precise MRD would add a reimbursed growth line the current price does not reflect.

The case that the deal gain holds breaks on a daily close below $4.21, the 19 October 2026 close. Another year-over-year fall in revenue per test, a revenue-guidance cut beyond the prenatal carve-out, or termination of the Labcorp agreement would confirm it.

What it trades with

Myriad trades mainly on its own news: the 20 October 2026 deal produced the 36.85% move, and the 1 September 2026 Piper Sandler cut drove the earlier fall. Among diagnostics peers, Natera is the closest comparison for MRD and hereditary testing; faster MRD growth there with no MRD revenue at Myriad would widen the gap. Labcorp, the buyer, takes on the prenatal regulatory review risk alongside Myriad. Payer behaviour, including denial rates and prior-authorization rules, hits the whole genetic-testing group at once.

Notes

  • Adjusted EBITDA guidance has been suspended since 30 July 2026 (prior $37–49M); the company has no profitability outlook until it is reinstated.
  • The Labcorp prenatal sale needs regulatory clearance and is expected to close in early 2027; the $210 million cash price is not received before closing.
  • Law-firm securities investigation notices have circulated since 4 August 2026 over the FY26 guidance sequence; an investigation notice is not a filed complaint.
  • At a single-digit share price, single analyst notes and company announcements move the shares sharply, as on 1 September 2026 and 20 October 2026.

Related · shared themes

See also · stocks to watch